Healthcare news on March 22, 2026

1. 0108:30 UTC

   Coverage recordnews.webindia123.com: “India MedTech, Pharma boom sign of shift to self - reliant healthcare growth: Jitendra Singh”

   2 outlets · first: newkerala.com Market trends

   Reports ran between 08:30 and 09:30 UTC on Mar 22.

   The outlets that reported this event are listed with links to their reports; no summary of ours passed our automated checks for it, which says nothing about the event (how they work).

   Reported by newkerala.com and news.webindia123.com.

   • Jitendra Singh

2. 0206:30 UTC

   Reports: China southern frontier region emerges as medical AI gateway to ASEAN

   2 outlets · first: english.news.cn Health IT

   Machine summary Reports say a region on China's southern frontier has emerged as a medical AI gateway to ASEAN.

   Reported by english.news.cn and en.people.cn.

   • ASEAN
   • Medical AI

   Full coverage: every report, when each was published, and who was named (2 outlets)

3. 0317:00 UTC

   Capricorn Investment Group Takes 1.7M Share Stake in HeartFlow (HTFL)

   2 outlets · first: finance.yahoo.com Funding

   Machine summary According to finance.yahoo.com, Capricorn Investment Group purchased 1.7 million HeartFlow shares.

   Reported by finance.yahoo.com and fool.com.

   • Capricorn Investment Group
   • Heartflow

4. 0420:26 UTC

   Structure Therapeutics Slides 28% in 2026 Amid New $6M Institutional Stake

   2 outlets · first: fool.com Market trends

   Machine summary Structure Therapeutics (GPCR) has experienced a 28% year-to-date decline in 2026, contrasting with its triple-digit gains over the previous year.

   1. B Group, Inc. initiated a new position of 90,000 shares worth $6.26 million.
   2. B Group's stake in GPCR represents 4.62% of its total reportable U.S. equity assets.

   Reported by fool.com and finance.yahoo.com.

   • Structure Therapeutics
   • B Group, Inc.

5. 0500:13 UTC

   Dafna Capital trims Axogen stake by 265,456 shares, SEC filing shows

   1 outlet · first: fool.com Market trends

   Machine summary Dafna Capital Management reduced its Axogen position by 265,456 shares in the fourth quarter of 2025, according to a February 17, 2026, SEC filing. The estimated transaction value was $6.53 million, based on quarterly average pricing, and the fund ended the period with 476,826 shares worth $15.61 million.

   1. According to a February 17, 2026, SEC filing, Dafna Capital Management reduced its Axogen position by 265,456 shares during the fourth quarter of 2025.
   2. Using the quarter's average closing price, the sale's transaction value was estimated at $6.53 million.
   3. The fund ended the period holding 476,826 Axogen shares, valued at $15.61 million when the quarter ended.
   4. Following the sale, Axogen accounts for 3.63% of the fund's assets under management that are 13F reportable.
   5. On Friday, Axogen stock traded at $30.78, a 71% gain from a year earlier.

   Reported by fool.com.

   • DAFNA Capital Management
   • AxoGen

6. 0609:30 UTC

   Eli Lilly has submitted orforglipron to the U.S.

   1 outlet · first: fool.com Market trends

   Machine summary Key facts from the reports:

   1. Mounjaro and Zepbound individually generated triple-digit revenue growth in the most recent quarter, and their combined total exceeded $11 billion for Eli Lilly.

   Reported by fool.com.

   • Eli Lilly
   • orforglipron

Each summary and its key facts are a machine summary of the reports linked under it; the outlets, times and counts come from those reports' own records. How a rundown is built.